替考拉宁治疗重型颅脑损伤合并重度医院感染肺炎临床疗效  

Treatment of Teicoplanin for Severe Brain Injury Complicated with Nosocomial Pneumonia

作　　者：魏伟[1] 田恒力[1] 曹合利[1] 胡锦[1] 徐涛[1] 

机构地区：[1]上海交通大学附属第六人民医院神经外科,上海200233

出　　处：《中华医院感染学杂志》2010年第3期394-396,共3页Chinese Journal of Nosocomiology

摘　　要：目的评价替考拉宁治疗重型颅脑损伤合并重度医院感染肺炎的临床疗效及安全性。方法收集重型颅脑损伤合并重度医院感染革兰阳性菌肺炎共43例，应用替考拉宁进行治疗，疗程7～14d。结果替考拉宁治疗后，患者痊愈31例，显效6例，痊愈率为72．1％，有效率为86．0％；细菌清除38例，清除率为88．4％；不良反应发生2例，发生率为4．7％。结论替考拉宁治疗重型颅脑损伤合并重度医院感染肺炎疗效好，不良反应相对较低，使用较为安全。OBJECTIVE To evaluate the efficacy and safety of teicoplanin on the patients with severe brain injury complicated with nosocomial pneumonia. METHODS A total of 43 cases with severe brain injury complicated with nosocomial pneumonia were recruited and treated with teicoplanin. The duration of the treatment was 7 to 14 days. RESULTS After the treatment of teicoplanin, 31 patients were cured and 6 patients were markedly effective, with the total cure rate 72.1% and the total response rate 86.0 %. From 43 strains 38 were killed and the clearing rate was 88.4%. Two patients had adverse reactions and the adverse reaction rate was 4, 7 %. CONCLUSIONS Teicoplanin is both effective and safety for patients with severe cerebral injury complicated with nosocomial pneumonia.

关 键 词：替考拉宁 重型颅脑损伤 肺炎 

分 类 号：R978.1[医药卫生—药品]